Riskpilot← Back to searchSign inGet full accessBiotechnology and Development ApS
APSActiveCVR 33870639Priorsvej 4AWholesale of other intermediate products · NACE 4686Est. 20112 employees
Revenue 2025
DKK 282K
+162% vs 2024
EBITDA margin
-0.8%
-103% vs 2024
Equity ratio
51.3%
Financial strength
Net profit 2025
DKK -2K
-103% vs 2024
| Revenue | DKK 282K | +162% |
| EBITDA | DKK -2K | -103% |
| Net profit | DKK -2K | -103% |
| Total assets | DKK 205K | +39% |
| Equity | DKK 105K | -2% |
| Employees | 2 | — |
Legal name
Biotechnology and Development ApS
CVR number
33870639
Legal form
Anpartsselskab
NACE code
4686 · Wholesale of other intermediate products
Founded
16. august 2011
Share capital
DKK 80.000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør eller af den samlede direktion
Company purpose
Selskabets formål er at drive handels- og udviklingsvirksomhed samt anden hermed efter direktionens skøn beslægtet virksomhed
Address
Priorsvej 4A
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -96 | -6 | -12 | 14 | 32 | 25 | 36 | 19 | 79 | -7 | 45 | 3 | 108 | 282 |
| Staff expenses | -0 | -0 | -0 | -0 | -13 | -26 | -25 | -24 | -21 | -24 | -22 | -22 | -23 | -284 |
| EBITDA | -96 | -6 | -12 | 14 | 19 | -1 | 11 | -5 | 58 | -31 | 23 | -19 | 85 | -2 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -96 | -6 | -12 | 14 | 19 | -1 | 11 | -5 | 58 | -31 | 23 | -19 | 85 | -2 |
| Net financials | -0 | 1 | -0 | -1 | -2 | -3 | -3 | -3 | -0 | 3 | 1 | -0 | -0 | -0 |
| Profit before tax | -96 | -5 | -12 | 13 | 17 | -4 | 8 | -8 | 58 | -28 | 24 | -19 | 85 | -2 |
| Tax | -23 | -1 | -3 | 3 | 4 | -1 | 2 | -0 | 11 | -6 | 5 | -4 | 19 | -0 |
| Net profit | -73 | -4 | -9 | 10 | 13 | -3 | 6 | -8 | 47 | -22 | 19 | -15 | 66 | -2 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 31 | 41 | 45 | 78 | 122 | 118 | 142 | 108 | 144 | 75 | 103 | 78 | 148 | 205 |
| Equity | 7 | 3 | -6 | 4 | 17 | 15 | 20 | 12 | 58 | 36 | 55 | 41 | 107 | 105 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 15 | 0 |
| Short-term debt | 25 | 38 | 51 | 74 | 105 | 103 | 122 | 96 | 86 | 39 | 42 | 37 | 26 | 100 |
| Total debt | 25 | 38 | 51 | 74 | 105 | 103 | 122 | 96 | 86 | 39 | 47 | 37 | 41 | 100 |
EBITDA margin
-0.8%
This company
15.8%
Market median
-105% vs market
20122025
Equity ratio
51.3%
This company
38.2%
Market median
+34% vs market
20122025
Return on equity
-1.6%
This company
18.4%
Market median
-109% vs market
20122025
Net profit margin
-0.6%
This company
8.1%
Market median
-107% vs market
20122025
Asset turnover
1.38×
This company
1.12×
Market median
+23% vs market
20122025
Debt / equity
0.95×
This company
0.62×
Market median
+53% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via CVR / Virk · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via CVR / Virk · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via CVR / Virk · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via CVR / Virk · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via CVR / Virk · Period 2015-07-01 – 2016-06-30
- Annual report 2015Filed via CVR / Virk · Period 2014-07-01 – 2015-06-30
- Annual report 2014Filed via CVR / Virk · Period 2013-07-01 – 2014-06-30
- Annual report 2013Filed via CVR / Virk · Period 2012-07-01 – 2013-06-30
- Annual report 2012Filed via CVR / Virk · Period 2011-08-16 – 2012-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KE Management | Management | 2011 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
KLMC Holding ApS | Company | 100.0% | 100.0% | 2011 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
KLMC Holding ApS
Biotechnology and Development ApS Board members of Biotechnology and Development ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl Erik Molbech | Management | 0 companies |